IL296518A - Methods for treating acute respiratory syndrome - Google Patents
Methods for treating acute respiratory syndromeInfo
- Publication number
- IL296518A IL296518A IL296518A IL29651822A IL296518A IL 296518 A IL296518 A IL 296518A IL 296518 A IL296518 A IL 296518A IL 29651822 A IL29651822 A IL 29651822A IL 296518 A IL296518 A IL 296518A
- Authority
- IL
- Israel
- Prior art keywords
- dantrolene
- administering
- subject
- sars
- host cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063008529P | 2020-04-10 | 2020-04-10 | |
| US202063062623P | 2020-08-07 | 2020-08-07 | |
| PCT/US2021/026303 WO2021207444A1 (en) | 2020-04-10 | 2021-04-08 | Methods of treating severe acute respiratory syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL296518A true IL296518A (en) | 2022-11-01 |
Family
ID=75690705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL296518A IL296518A (en) | 2020-04-10 | 2021-04-08 | Methods for treating acute respiratory syndrome |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12582633B2 (https=) |
| EP (1) | EP4132516A1 (https=) |
| JP (1) | JP2023521162A (https=) |
| KR (1) | KR20220167292A (https=) |
| CN (1) | CN115916189A (https=) |
| AU (1) | AU2021254415A1 (https=) |
| BR (1) | BR112022020107A2 (https=) |
| CA (1) | CA3174684A1 (https=) |
| IL (1) | IL296518A (https=) |
| MX (1) | MX2022012707A (https=) |
| WO (1) | WO2021207444A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12605364B2 (en) * | 2020-04-10 | 2026-04-21 | Eagle Pharmaceuticals, Inc. | Methods of treating SARS-CoV-2 infections |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY201417A (en) | 2017-10-20 | 2024-02-21 | Eagle Res Labs Limited | Dantrolene prodrugs and methods of their use |
| US11123328B2 (en) | 2017-11-14 | 2021-09-21 | University Health Network | Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction |
| WO2019175761A1 (en) | 2018-03-12 | 2019-09-19 | Orbicular Pharmaceutical Technologies Private Limited | Ready to use dantrolene compositions |
| US12246028B2 (en) | 2018-11-27 | 2025-03-11 | Eagle Research Labs Limited | Use of dantrolene and dantrolene prodrugs to treat radiation exposure |
| US12605364B2 (en) | 2020-04-10 | 2026-04-21 | Eagle Pharmaceuticals, Inc. | Methods of treating SARS-CoV-2 infections |
-
2021
- 2021-04-08 AU AU2021254415A patent/AU2021254415A1/en active Pending
- 2021-04-08 WO PCT/US2021/026303 patent/WO2021207444A1/en not_active Ceased
- 2021-04-08 CA CA3174684A patent/CA3174684A1/en active Pending
- 2021-04-08 MX MX2022012707A patent/MX2022012707A/es unknown
- 2021-04-08 JP JP2022561996A patent/JP2023521162A/ja active Pending
- 2021-04-08 EP EP21722062.3A patent/EP4132516A1/en active Pending
- 2021-04-08 IL IL296518A patent/IL296518A/en unknown
- 2021-04-08 US US17/995,604 patent/US12582633B2/en active Active
- 2021-04-08 CN CN202180031027.5A patent/CN115916189A/zh active Pending
- 2021-04-08 KR KR1020227037111A patent/KR20220167292A/ko active Pending
- 2021-04-08 BR BR112022020107A patent/BR112022020107A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US12582633B2 (en) | 2026-03-24 |
| EP4132516A1 (en) | 2023-02-15 |
| WO2021207444A1 (en) | 2021-10-14 |
| CA3174684A1 (en) | 2021-10-14 |
| AU2021254415A1 (en) | 2022-10-20 |
| US20230149363A1 (en) | 2023-05-18 |
| CN115916189A (zh) | 2023-04-04 |
| BR112022020107A2 (pt) | 2022-11-29 |
| KR20220167292A (ko) | 2022-12-20 |
| MX2022012707A (es) | 2023-01-05 |
| JP2023521162A (ja) | 2023-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA036505B1 (ru) | Способ лечения заболевания или состояния, вызванного вирусом, принадлежащим к роду enterovirus | |
| JP2022533876A (ja) | Ｃｏｖｉｄ－１９新型コロナ肺炎を予防又は治療する医薬品、食品及びその使用 | |
| IL296518A (en) | Methods for treating acute respiratory syndrome | |
| IL296517A (en) | Methods of treating sars-cov-2 infections | |
| US20230181509A1 (en) | The use of diffusion enhancing compounds for treatment of viral and bacterial induced respiratory disease | |
| WO2021188787A1 (en) | Method for treatment of coronavirus infection | |
| CA3178985A1 (en) | Treatment of known and unknown viral infection with lipid agents | |
| WO2021255226A1 (en) | Antiviral use of calixarenes | |
| Koelsch et al. | Anti-rhinovirus-specific activity of the alpha-sympathomimetic oxymetazoline | |
| EP4132519A1 (en) | Methods of treating coronavirus infections | |
| HK40083259A (en) | Dantrolene for use in methods of treating sars-cov-2 infections | |
| HK40083259B (en) | Dantrolene for use in methods of treating sars-cov-2 infections | |
| WO2021207446A1 (en) | Methods of treating viral infections | |
| HK40090314A (zh) | 治疗严重急性呼吸综合征的方法 | |
| KR20210129579A (ko) | 사스 코로나바이러스 감염증 치료용 약학적 조성물 | |
| ES2938574T3 (es) | Péptido para la prevención o el tratamiento de la COVID-19 | |
| TW202102224A (zh) | 使用經取代之多環吡啶酮衍生物及其前藥於患有流感及嚴重流感病況之個體中治療流感 | |
| Michie | MYOCARDITIS IN A FATAL CASE OF H1N1 INFLUENZA. |